-
Gilgeous-Alexander scores 40 as Thunder clinch playoff berth
-
Venezuela stun United States to win World Baseball Classic
-
Stocks extend gains and oil dips as US, Israel, Iran continue strikes
-
Iran missile fire kills two in central Israel: medics
-
Britain, Rwanda in £100m court clash over migrant deal
-
'We will wait for each one': Ukrainians greet POWs with tears and cheers
-
UN watchdog says projectile struck Iran nuclear power plant
-
Trump faces impasse over Iran war
-
US Fed expected to hold rates steady as Iran war's shockwaves ripple
-
Former Australian Test wicketkeeper Haddin to coach NSW
-
China coach says team on right track despite Asian Cup heartache
-
Oscars audience drops, viewing figures show
-
Resilient Australia 'need to be better' in Women's Asian Cup final
-
Gio Reyna picked for US squad as Pochettino says World Cup roster still 'open'
-
Colombia, Ecuador leaders clash over bomb dropped near border
-
PSG, Real Madrid and Arsenal march into Champions League last eight
-
'Incomplete' Man City not what they once were, says Guardiola
-
US judge orders Trump admin to bring VOA employees back to work
-
White House pressure on Cuba mounts as island fights power cut
-
Arteta hails 'magical' Eze after Arsenal star sinks Leverkusen
-
Senegal stripped of AFCON title, Morocco declared champions
-
Nvidia says restarting production of China-bound chips
-
Panic as Israel army urges residents to evacuate south Lebanon's Tyre area
-
Real Madrid 'change' under Champions League spotlight: Vinicius
-
Real Madrid dump Man City out of Champions League once more
-
Clinical PSG bury Chelsea to reach Champions League quarter-finals
-
Eze rocket fires Arsenal into Champions League quarters
-
US airlines still see strong demand as jet fuel worries loom
-
Milei blasts Iran on anniversary of attack on Israeli embassy
-
USS Gerald R. Ford: the world's biggest aircraft carrier
-
US, European stocks rise despite latest jump in oil prices
-
Sporting Lisbon thrash Bodo/Glimt to reach Champions League quarters
-
Irish PM pushes Trump on Iran -- politely
-
Arizona charges prediction market Kalshi with illegal election betting
-
Leftist New York mayor under pressure on Irish unity question
-
Atletico boss Simeone defends Spurs star Romero
-
Iran vets friendly ships for Hormuz passage: trackers
-
Iran women's football team arrive in Turkey on way home
-
Mexico prepared to host Iran World Cup games, says president
-
Trump blasts 'foolish' NATO on Iran, says US needs no help
-
Slot vows to win back support of frustrated Liverpool fans
-
In Ukraine, Sean Penn gifted Oscar made from train carriage hit by Russia
-
Ships in Gulf risk shortages on board, industry warns
-
White House piles pressure on Cuba as island fights power cut
-
Newcastle must grow under Camp Nou pressure: Howe
-
Trump says to make delayed China trip in 'five or six weeks'
-
Kompany warns of complacency as injury-hit Bayern host Atalanta
-
SAS cancels flights after fuel prices surge
-
New particle discovered by Large Hadron Collider
-
Lebanon says Israeli strikes kill soldiers, as shelters overflow
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
O.Johnson--AMWN